Menne J, et al. - Experts evaluated the impact of eculizumab, a terminal complement inhibitor, on complement-mediated thrombotic microangiopathy (TMA) in atypical haemolytic-uraemic syndrome (aHUS) patients. An increased risk of TMA manifestations after discontinuation of eculizumab or in the setting of non-labelled eculizumab dosing was seen in patients with aHUS. Findings suggested that particularly in patients with identified complement abnormalities, eculizumab treatment minimized the risk of TMA. More frequently TMA manifestations with hospitalizations/serious AEs occurred off vs on treatment.